GXI has been the subject of a number of other research reports. JPMorgan Chase & Co. set a €87.70 ($108.27) price objective on shares of Gerresheimer and gave the company a buy rating in a research report on Thursday, January 4th. Credit Suisse Group set a €75.00 ($92.59) price objective on shares of Gerresheimer and gave the company a buy rating in a research report on Wednesday, February 21st. DZ Bank reissued a buy rating on shares of Gerresheimer in a research report on Monday, February 26th. Deutsche Bank set a €64.00 ($79.01) price objective on shares of Gerresheimer and gave the company a neutral rating in a research report on Friday, December 1st. Finally, Hauck & Aufhaeuser set a €55.00 ($67.90) target price on shares of Gerresheimer and gave the company a sell rating in a report on Wednesday, January 24th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. The company presently has an average rating of Hold and an average target price of €69.85 ($86.24).
Gerresheimer stock opened at €66.70 ($82.35) on Friday. The firm has a market cap of $2,100.00 and a P/E ratio of 20.78. Gerresheimer has a 52-week low of €59.97 ($74.04) and a 52-week high of €78.25 ($96.60).
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.